-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

Benzinga·10/29/2026 21:16:28
Listen to the news
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.